TG Therapeutics (TGTX) Q1 2026 earnings review
Flawless Top-Line Execution Masks Sudden Margin Compression
TG Therapeutics delivered a massive beat in Q1, with BRIUMVI U.S. sales hitting $194.8M (+63% YoY), driving a major guidance hike for FY26 to $885-$900M. The commercial momentum is undeniable, with Q2 targeted at an Accelerating $220M. However, operating leverage took a hit. SG&A expenses exploded by 75% YoY to $88.2M, causing the operating margin to Reverse sharply from 26.2% in 25Q4 to 17.0% in 26Q1. While the $500M non-dilutive capital injection from Blue Owl provides a war chest for buybacks and subcutaneous manufacturing, the ballooning commercial spend requires strict monitoring to ensure it yields proportional bottom-line returns.
🐂 Bull Case
The Q2 guidance of ~$220M implies a +$25.2M sequential addition, faster than the +$12.1M added in Q1. The drug is taking significant share in the IV anti-CD20 market.
Both the subcutaneous BRIUMVI Phase 3 trial and the ENHANCE (consolidated Day 1/15 dose) Phase 3 program have completed enrollment, setting up major catalysts for late 2026.
🐻 Bear Case
Despite a massive revenue scale-up, operating margins compressed sequentially from 26.2% to 17.0% due to severe SG&A spending ($88.2M in Q1 alone).
Securing $500M in 'non-dilutive capital' from Blue Owl will likely introduce significant interest expense or royalty burdens, directly impacting future net income.
⚖️ Verdict: 🟢
Bullish. The top-line momentum and forward guidance are exceptional, proving the commercial model works. However, the sudden spike in SG&A prevents a perfect score.
Key Themes
BRIUMVI Commercial Penetration
Growth remains remarkably Stable and robust. BRIUMVI U.S. net product revenue of $194.8M reflects 63% YoY growth. Management notes 'record new patient starts' and 'strong underlying demand'. The guide to $220M for Q2 indicates that early commercial momentum is sustainable and continuing to compound.
Innovation: ENHANCE & Subcutaneous Trials Enrolled
The company has fully enrolled its two most important lifecycle extension trials: the Phase 3 subcutaneous BRIUMVI program and the Phase 3 ENHANCE trial (consolidating Day 1 and Day 15 IV doses). Topline ENHANCE data is expected mid-year 2026. This is a critical driver for defending market share against competitors' at-home therapies.
Severe Margin Compression due to SG&A Ramp
Operating margin Reversing. Total SG&A jumped 75% YoY to $88.2M. While revenue grew 63%, operating leverage stalled. Q1 Net Income was just $19.8M on $204.9M of revenue. The margin deterioration contradicts the narrative of a maturing, hyper-profitable franchise and indicates customer acquisition costs are rising as the company expands its marketing and media spend.
The $500M Blue Owl Capital Cost
Management secured $500M in non-dilutive capital from Blue Owl. While this bolsters the balance sheet to $572.8M and funds an expanded $300M share repurchase program, 'non-dilutive' capital is never free. It introduces either heavy debt-service costs (interest expense already climbed to $7.7M in Q1) or royalty encumbrances that will tax future cash flows.
Macro: Supply Chain and Tariff Vulnerabilities
The company continues to flag the 'imposition of tariffs' as a major risk in its safe harbor. Because BRIUMVI is currently manufactured in South Korea, the asset is heavily exposed to rising global trade tensions. While management previously stated low cost-of-goods buffers this impact, broad tariff changes could pressure future gross margins before the planned U.S. manufacturing footprint matures.
Other KPIs
Revenue from the Neuraxpharm partnership is comprised of $6.5M in product sales, $2.7M in royalties, and $0.9M for development activities. While small compared to the U.S. business, this represents a Steady supplemental cash flow stream.
Accelerating dramatically from $199.5M at the end of FY25, driven by the $500M Blue Owl financing. The company used $100M of this to execute share repurchases in Q1 at an average price of $29.28, signaling management's belief that shares remain undervalued.
Stable YoY (up just $2M from 25Q1). The expense mix shifted: lower manufacturing costs for subcutaneous ublituximab were offset by a milestone payment to Precision BioSciences and higher clinical trial execution costs.
Guidance
Accelerating/Stable. Raised from the ~$887.5M midpoint implied in the prior quarter. This represents roughly 50% YoY growth vs FY25's ~$616M total revenue, showcasing immense confidence in near-term demand.
Accelerating. Raised considerably from the prior $825-$850M target. Achieving the $892.5M midpoint requires an average quarterly run rate of ~$232M for the rest of the year.
Accelerating. Up sequentially from $194.8M in Q1. This implies a QoQ growth jump of roughly 13%, shaking off the typical Q1 seasonality impacts and highlighting aggressive volume uptake.
With Q1 SG&A and R&D already totaling $136.6M (including stock comp), achieving the $350M base target (excluding non-cash) implies spending must be aggressively controlled in the coming quarters, or guidance will need to be raised. The extra $100M for subcu manufacturing will further pressure near-term reported profitability.
Key Questions
Runaway SG&A vs OpEx Guidance
SG&A hit $88.2M in Q1. Even stripping out non-cash comp, are you pacing to break your $350M base OpEx guidance, or do you expect commercial and media spend to step down sequentially for the rest of the year?
Blue Owl Capital Terms
What are the exact structural terms of the $500M Blue Owl capital? What interest rate, royalty percentage, or covenants are attached, and how will this drag on net income going forward?
ENHANCE Trial Market Impact
With ENHANCE topline data expected mid-year 2026, assuming positive results, how quickly can the label be updated, and what percentage of your current IV patients do you expect to transition to the consolidated Day 1 dose?
Ex-U.S. Subcutaneous Strategy
With the subcutaneous Phase 3 trial fully enrolled, has your European partner Neuraxpharm explicitly opted into the commercialization of the subcu formulation, and what milestones are attached to that transition?